Prosight Management LP Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Prosight Management LP bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 920,000 shares of the biopharmaceutical company's stock, valued at approximately $8,666,000. Amicus Therapeutics accounts for approximately 2.4% of Prosight Management LP's investment portfolio, making the stock its 15th largest holding. Prosight Management LP owned approximately 0.31% of Amicus Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after purchasing an additional 458,143 shares during the period. Wellington Management Group LLP increased its holdings in shares of Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after purchasing an additional 159,139 shares during the period. Northern Trust Corp increased its holdings in shares of Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock valued at $31,761,000 after purchasing an additional 187,652 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Amicus Therapeutics by 3.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company's stock valued at $30,779,000 after buying an additional 107,348 shares in the last quarter.

Amicus Therapeutics Stock Down 2.3%

FOLD opened at $5.88 on Thursday. The business's fifty day moving average is $7.47 and its two-hundred day moving average is $8.99. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -32.67, a PEG ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a one year low of $5.82 and a one year high of $12.65.

Analysts Set New Price Targets

FOLD has been the topic of a number of analyst reports. The Goldman Sachs Group decreased their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Wells Fargo & Company decreased their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. UBS Group lifted their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.